Refractory Non Hodgkin Lymphoma clinical trials

Explore recruiting refractory non hodgkin lymphoma clinical trials.

Recruiting refractory non hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Non Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HOVON 161: A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

Germany, Italy, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) )

Germany, Spain, Denmark, Italy, Sweden, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory BCell Non Hodgkin Lymphoma (ZUMA-4)

Spain, Czechia, France, Italy, Poland, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Refractory Non Hodgkin Lymphoma trials by city

Refractory Non Hodgkin Lymphoma in Toronto Refractory Non Hodgkin Lymphoma in Vancouver Refractory Non Hodgkin Lymphoma in Montreal Refractory Non Hodgkin Lymphoma in Calgary Refractory Non Hodgkin Lymphoma in Edmonton Refractory Non Hodgkin Lymphoma in Ottawa Refractory Non Hodgkin Lymphoma in Winnipeg Refractory Non Hodgkin Lymphoma in Quebec City Refractory Non Hodgkin Lymphoma in Hamilton Refractory Non Hodgkin Lymphoma in Kitchener Refractory Non Hodgkin Lymphoma in London Refractory Non Hodgkin Lymphoma in Halifax Refractory Non Hodgkin Lymphoma in New York Refractory Non Hodgkin Lymphoma in Los Angeles Refractory Non Hodgkin Lymphoma in Chicago Refractory Non Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease